Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer

BACKGROUND: The Food and Drug Administration recommends that people living with HIV (PWH) with a CD4+ T cell count (CD4) ≥350 cells/µL may be eligible for any cancer clinical trial, but there is reluctance to enter patients with lower CD4 counts into cancer studies, including immune checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Odeny, Thomas A, Lurain, Kathryn, Strauss, Julius, Fling, Steven P, Sharon, Elad, Wright, Anna, Martinez-Picado, Javier, Moran, Teresa, Gulley, James L, Gonzalez-Cao, Maria, Uldrick, Thomas S, Yarchoan, Robert, Ramaswami, Ramya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442492/
https://www.ncbi.nlm.nih.gov/pubmed/37935055
http://dx.doi.org/10.1136/jitc-2022-005128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442492/
https://www.ncbi.nlm.nih.gov/pubmed/37935055
http://dx.doi.org/10.1136/jitc-2022-005128

Ejemplares similares